You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 5, 2024

CLINICAL TRIALS PROFILE FOR CEFEPIME HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Cefepime Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00020865 ↗ Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status National Cancer Institute (NCI) Phase 3 2001-09-01 RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer. It is not yet known whether levofloxacin is more effective than cefepime in reducing fever and controlling symptoms of neutropenia. PURPOSE: Randomized phase III trial to compare the effectiveness of levofloxacin with that of cefepime in reducing fever and controlling symptoms of neutropenia in patients who are being treated for cancer.
NCT00020865 ↗ Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status Jonsson Comprehensive Cancer Center Phase 3 2001-09-01 RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer. It is not yet known whether levofloxacin is more effective than cefepime in reducing fever and controlling symptoms of neutropenia. PURPOSE: Randomized phase III trial to compare the effectiveness of levofloxacin with that of cefepime in reducing fever and controlling symptoms of neutropenia in patients who are being treated for cancer.
NCT00044759 ↗ Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 1969-12-31 To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma.
NCT00137787 ↗ Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases Completed Bayer Phase 3 2005-04-01 The aim of this study is to investigate whether intravenous ciprofloxacin is as effective as cefepime for the initial treatment of febrile neutropenia developed in patients with hematologic diseases.
NCT00137787 ↗ Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases Completed Center for Supporting Hematology-Oncology Trials Phase 3 2005-04-01 The aim of this study is to investigate whether intravenous ciprofloxacin is as effective as cefepime for the initial treatment of febrile neutropenia developed in patients with hematologic diseases.
NCT00358202 ↗ Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia Completed Elan Pharmaceuticals Phase 4 2002-03-01 Randomized trial of nursing home residents with pneumonia to assess if intramuscular cefepime is a safe, efficacious, and cost-effective alternative to once daily intramuscular ceftriaxone for the treatment of elderly nursing home residents who develop pneumonia and do not require hospitalization.
NCT00358202 ↗ Cefepime vs. Ceftriaxone to Treat Nursing Home-Acquired Pneumonia Completed CPL Associates Phase 4 2002-03-01 Randomized trial of nursing home residents with pneumonia to assess if intramuscular cefepime is a safe, efficacious, and cost-effective alternative to once daily intramuscular ceftriaxone for the treatment of elderly nursing home residents who develop pneumonia and do not require hospitalization.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Cefepime Hydrochloride

Condition Name

Condition Name for Cefepime Hydrochloride
Intervention Trials
Febrile Neutropenia 5
Complicated Urinary Tract Infection 5
Acute Pyelonephritis 5
Healthy Subjects 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Cefepime Hydrochloride
Intervention Trials
Infections 17
Communicable Diseases 15
Infection 14
Urinary Tract Infections 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Cefepime Hydrochloride

Trials by Country

Trials by Country for Cefepime Hydrochloride
Location Trials
United States 73
Spain 10
Poland 8
India 8
Brazil 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Cefepime Hydrochloride
Location Trials
Texas 10
California 7
Florida 5
New York 5
Pennsylvania 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Cefepime Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Cefepime Hydrochloride
Clinical Trial Phase Trials
Phase 4 14
Phase 3 19
Phase 2/Phase 3 1
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Cefepime Hydrochloride
Clinical Trial Phase Trials
Completed 27
Not yet recruiting 9
Terminated 8
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Cefepime Hydrochloride

Sponsor Name

Sponsor Name for Cefepime Hydrochloride
Sponsor Trials
Wockhardt 6
M.D. Anderson Cancer Center 5
National Cancer Institute (NCI) 3
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Cefepime Hydrochloride
Sponsor Trials
Other 60
Industry 36
NIH 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.